LALPATHLAB2020-01-012020-03-31in-bse-fin:OneOperatingExpenses01Member LALPATHLAB2020-01-012020-03-31in-bse-fin:OneOperatingExpenses02Member LALPATHLAB2020-01-012020-03-31in-bse-fin:FourOperatingExpenses01Member LALPATHLAB2020-01-012020-03-31in-bse-fin:FourOperatingExpenses02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares LALPATHLAB 2019-04-01 2020-03-31 2020-05-07 INR Millions Yearly Single segment the business of running laboratories for carrying out Pathological investigations of various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations. 2020-01-01 2020-03-31 Audited Standalone 2875000000.00 140000000.00 3015000000.00 686000000.00 0.00 0.00 589000000.00 37000000.00 185000000.00 1042000000.00 2539000000.00 476000000.00 0.00 476000000.00 150000000.00 -27000000.00 123000000.00 0.00 353000000.00 0.00 0.00 0.00 0.00 353000000.00 -22000000.00 331000000.00 0.00 0.00 833000000.00 10 4.28 4.27 0.00 0.00 4.28 4.27 0.00 0.00 0.00 1.tThe above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 18 May, 2020. The financial results for the year ended 31 March, 2020 have been audited and for the quarter ended 31 March, 2020 have been reviewed by the statutory auditors of the Company and they have expressed an unmodified opinion thereon. n2.tThese financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) as notified by Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and other accounting principles generally accepted in India. n3.tFigures for the quarter ended 31 March, 2020 and 31 March, 2019 are the balancing figures between the audited figures in respect of full financial year and the published year to date unaudited figures up to the third quarter ended 31 December, 2019 and 31 December, 2018 respectively, which was subjected to limited review. n4.tDuring the year ended 31 March, 2020, the Company has issued 3,267 equity shares of face value of Rs. 10 each on exercise of employee stock options. n5.tEffective 1 April, 2019, Ind AS 116 Leases” has been adopted by the Company using the modified retrospective transition method. Accordingly, the comparatives for earlier periods presented have not been restated. This has resulted in recognising right of use of assets amounting to INR 1,437 million and lease liabilities amounting to INR 1,280 million. Consequently on transition to Ind AS 116, profit before tax for the current quarter and year ended 31 March 2020 is lower by INR 21 million and 92 million respectively. n6.tDuring the quarter ended 30 June, 2019, 30 September, 2019 and 31 December, 2019 the Company has made a further investment of INR 30 million, INR 500 million and INR 69 milion respectively in its wholly owned subsidiary, Pathlabs Unifiers Private Limited, through subscription of additional equity shares. n7.tDuring the quarter ended 31 March 2020, the Company has made a further investment of INR 9 million in its wholly owned subsidiary, Dr. Lal Ventures Private Limited, through subscription of additional equity shares. n8.tDuring the year ended 31 March, 2020, a new wholly owned subsidiary, Dr. Lal PathLabs Kenya Private Limited has been incorporated in Kenya. The Company has subscribed to equity share capital amounting to INR 7 million in the subsidiary. n9.tThe Board of Directors of the Company had approved interim dividends, each of Rs. 6 per equity share (face value of Rs. 10 each) at their meetings held on 8 November, 2019 and 25 February, 2020 which was paid during the quarter ended 31 December, 2019 and quarter ended 31 March, 2020 respectively. n10.tThe Board of Directors in their meeting held on 3 February, 2020 have approved the “Scheme of Amalgamation” of APL Institute of Clinical Laboratory & Research Private Limited with the Company w.e.f. 1 April, 2020 (the appointed date). As per the said scheme the undertaking of this company shall stand transferred to and vested in the Company on a going concern basis without any further act, deed of matter. The scheme of amalgamation is subject to approval by the shareholders, National Company Law Tribunal and other statutory approvals. n nDue to size constraint Note no. 11, 12, 13 & 14 cannot be given here, for complete notes please refer PDF file for Financial Results – 31.03.2020. Single segment 2019-04-01 2020-03-31 Audited Standalone 12736000000.00 576000000.00 13312000000.00 2869000000.00 0.00 0.00 2321000000.00 147000000.00 680000000.00 4268000000.00 10285000000.00 3027000000.00 0.00 3027000000.00 802000000.00 -7000000.00 795000000.00 0.00 2232000000.00 0.00 0.00 0.00 0.00 2232000000.00 -11000000.00 2221000000.00 0.00 0.00 833000000.00 10 0.00 27.09 27.04 0.00 0.00 27.09 27.04 0.00 0.00 0.00 Fees to collection centers/channel partners 385000000.00 Other expenses 657000000.00 Fees to collection centers/channel partners 1696000000.00 Other expenses 2572000000.00